Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04784715




Registration number
NCT04784715
Ethics application status
Date submitted
19/02/2021
Date registered
5/03/2021
Date last updated
13/06/2024

Titles & IDs
Public title
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
Scientific title
Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
Secondary ID [1] 0 0
2020-004074-21
Secondary ID [2] 0 0
D967UC00001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Trastuzumab deruxtecan
Treatment: Drugs - Placebo
Treatment: Drugs - Taxane
Treatment: Drugs - Pertuzumab
Treatment: Drugs - Trastuzumab

Experimental: Arm A - Trastuzumab deruxtecan (T-DXd) plus pertuzumab-matching placebo

Experimental: Arm B - Trastuzumab deruxtecan (T-DXd) plus pertuzumab

Active Comparator: Arm C - Standard of care (Taxane (paclitaxel or docetaxel), trastuzumab, and pertuzumab)


Treatment: Drugs: Trastuzumab deruxtecan
Administered by intravenous infusion

Treatment: Drugs: Placebo
Administered by intravenous infusion

Treatment: Drugs: Taxane
Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion

Treatment: Drugs: Pertuzumab
Administered by intravenous infusion

Treatment: Drugs: Trastuzumab
Administered by intravenous infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment
Timepoint [1] 0 0
Until progression or death, assessed up to approximately 60 months
Secondary outcome [1] 0 0
Progression Free Survival (PFS) by Investigator assessment
Timepoint [1] 0 0
Until progression or death, assessed up to approximately 60 months
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Until death, assessed up to approximately 104 months
Secondary outcome [3] 0 0
Objective Response Rate (ORR) by BICR and Investigator assessment
Timepoint [3] 0 0
Until progression or death (in the absence of progression), assessed up to approximately 60 months
Secondary outcome [4] 0 0
Duration of Response (DoR) by BICR and Investigator Assessment
Timepoint [4] 0 0
Until progression or death (in the absence of progression), assessed up to approximately 60 months
Secondary outcome [5] 0 0
Time to second progression or death (PFS2) by Investigator assessment
Timepoint [5] 0 0
Assessed up to approximately 104 months
Secondary outcome [6] 0 0
To assess the effect of T-DXd ± pertuzumab relative to THP in terms of patient-reported pain in participants with HER2 positive, first-line mBC'.
Timepoint [6] 0 0
Assessed up to approximately 60 months
Secondary outcome [7] 0 0
To assess patient-reported treatment tolerability
Timepoint [7] 0 0
Assessed up to approximately 60 months
Secondary outcome [8] 0 0
To assess patient-reported treatment tolerability
Timepoint [8] 0 0
Assessed up to approximately 60 months
Secondary outcome [9] 0 0
To assess patient-reported treatment tolerability
Timepoint [9] 0 0
Assessed up to approximately 60 months
Secondary outcome [10] 0 0
To assess patient-reported treatment tolerability
Timepoint [10] 0 0
Assessed up to approximately 60 months
Secondary outcome [11] 0 0
To assess patient-reported treatment tolerability
Timepoint [11] 0 0
Assessed up to approximately 60 months
Secondary outcome [12] 0 0
Serum concentration of trastuzumab deruxtecan and pertuzumab
Timepoint [12] 0 0
Up to Cycle 6, approximately Week 18; each cycle is 21 days
Secondary outcome [13] 0 0
Immunogenicity of trastuzumab deruxtecan.
Timepoint [13] 0 0
Up to follow-up period, approximately 60 months
Secondary outcome [14] 0 0
Safety and tolerability of trastuzumab deruxtecan, alone or with pertuzumab
Timepoint [14] 0 0
Assessed up to approximately 60 months

Eligibility
Key inclusion criteria
Key

* Patients must be =18 years of age
* Pathologically documented breast cancer that:

1. is advanced or metastatic
2. is locally assessed and prospectively centrally confirmed as HER2-positive (IHC3+ or ISH+)
3. is documented by local testing as hormone receptor (HR)-positive or HR-negative disease in the metastatic setting
* No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer or only 1 previous line of endocrine therapy in the metastatic setting. Participants who have received chemotherapy or HER2-targeted therapy in the neo-adjuvant or adjuvant setting are eligible if > 6 months from treatment to metastatic diagnosis.
* Has protocol-defined adequate organ and bone marrow function
* ECOG performance status 0 or 1

Key
Minimum age
18 Years
Maximum age
130 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Ineligible for any of the agents on the study.
* Any substance abuse or other medical conditions that, in the investigator's opinion, may interfere with subject's participation or study results
* Patients with spinal cord compression or clinically active central nervous system metastases. Participants with clinically inactive brain metastases or treated brain metastases that are no longer symptomatic may be included in the study.
* Active or prior documented interstitial lung disease (ILD)/pneumonitis or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
* Prior randomization or treatment in a previous trastuzumab deruxtecan study regardless of treatment arm assignment

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/04/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/12/2029
Actual
Sample size
Target
Accrual to date
Final
1157
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Mississippi
Country [15] 0 0
United States of America
State/province [15] 0 0
Nebraska
Country [16] 0 0
United States of America
State/province [16] 0 0
Nevada
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Dakota
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Dakota
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Utah
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
Argentina
State/province [29] 0 0
Caba
Country [30] 0 0
Argentina
State/province [30] 0 0
Capital Federal
Country [31] 0 0
Argentina
State/province [31] 0 0
Cipolletti
Country [32] 0 0
Argentina
State/province [32] 0 0
Ciudad Autonoma De Buenos Aire
Country [33] 0 0
Argentina
State/province [33] 0 0
Ciudad de Buenos Aires
Country [34] 0 0
Argentina
State/province [34] 0 0
La Plata
Country [35] 0 0
Argentina
State/province [35] 0 0
Mar del Plata
Country [36] 0 0
Argentina
State/province [36] 0 0
Rosario
Country [37] 0 0
Argentina
State/province [37] 0 0
San Salvador de Jujuy
Country [38] 0 0
Austria
State/province [38] 0 0
Innsbruck
Country [39] 0 0
Austria
State/province [39] 0 0
Wien
Country [40] 0 0
Belgium
State/province [40] 0 0
Brussels
Country [41] 0 0
Belgium
State/province [41] 0 0
Bruxelles
Country [42] 0 0
Belgium
State/province [42] 0 0
Charleroi
Country [43] 0 0
Belgium
State/province [43] 0 0
Edegem
Country [44] 0 0
Belgium
State/province [44] 0 0
Gent
Country [45] 0 0
Belgium
State/province [45] 0 0
Leuven
Country [46] 0 0
Belgium
State/province [46] 0 0
Liège
Country [47] 0 0
Belgium
State/province [47] 0 0
Namur
Country [48] 0 0
Brazil
State/province [48] 0 0
Barretos
Country [49] 0 0
Brazil
State/province [49] 0 0
Brasília
Country [50] 0 0
Brazil
State/province [50] 0 0
Florianópolis
Country [51] 0 0
Brazil
State/province [51] 0 0
Goiânia
Country [52] 0 0
Brazil
State/province [52] 0 0
Londrina
Country [53] 0 0
Brazil
State/province [53] 0 0
Natal
Country [54] 0 0
Brazil
State/province [54] 0 0
Porto Alegre
Country [55] 0 0
Brazil
State/province [55] 0 0
Ribeirão Preto
Country [56] 0 0
Brazil
State/province [56] 0 0
Sorocaba
Country [57] 0 0
Brazil
State/province [57] 0 0
São Paulo
Country [58] 0 0
Brazil
State/province [58] 0 0
Vitoria
Country [59] 0 0
Canada
State/province [59] 0 0
Alberta
Country [60] 0 0
Canada
State/province [60] 0 0
Nova Scotia
Country [61] 0 0
Canada
State/province [61] 0 0
Ontario
Country [62] 0 0
Canada
State/province [62] 0 0
Quebec
Country [63] 0 0
Canada
State/province [63] 0 0
Saskatchewan
Country [64] 0 0
China
State/province [64] 0 0
Beijing
Country [65] 0 0
China
State/province [65] 0 0
Changchun
Country [66] 0 0
China
State/province [66] 0 0
Changsha
Country [67] 0 0
China
State/province [67] 0 0
Chengdu
Country [68] 0 0
China
State/province [68] 0 0
Chongqing
Country [69] 0 0
China
State/province [69] 0 0
Dalian
Country [70] 0 0
China
State/province [70] 0 0
Guangzhou
Country [71] 0 0
China
State/province [71] 0 0
Guiyang
Country [72] 0 0
China
State/province [72] 0 0
Hangzhou
Country [73] 0 0
China
State/province [73] 0 0
Harbin
Country [74] 0 0
China
State/province [74] 0 0
Hefei
Country [75] 0 0
China
State/province [75] 0 0
Kunming
Country [76] 0 0
China
State/province [76] 0 0
Nanchang
Country [77] 0 0
China
State/province [77] 0 0
Nanjing
Country [78] 0 0
China
State/province [78] 0 0
Nanning
Country [79] 0 0
China
State/province [79] 0 0
Qingdao
Country [80] 0 0
China
State/province [80] 0 0
Shanghai
Country [81] 0 0
China
State/province [81] 0 0
Shenyang
Country [82] 0 0
China
State/province [82] 0 0
Shenzhen
Country [83] 0 0
China
State/province [83] 0 0
Tianjin
Country [84] 0 0
China
State/province [84] 0 0
Wu Han
Country [85] 0 0
China
State/province [85] 0 0
Wuhan
Country [86] 0 0
China
State/province [86] 0 0
Xi'an
Country [87] 0 0
China
State/province [87] 0 0
Yinchuan
Country [88] 0 0
China
State/province [88] 0 0
Zhengzhou
Country [89] 0 0
Denmark
State/province [89] 0 0
Aalborg
Country [90] 0 0
Denmark
State/province [90] 0 0
Copenhagen O
Country [91] 0 0
Denmark
State/province [91] 0 0
Odense C
Country [92] 0 0
Denmark
State/province [92] 0 0
Sønderborg
Country [93] 0 0
Denmark
State/province [93] 0 0
Vejle
Country [94] 0 0
France
State/province [94] 0 0
Avignon
Country [95] 0 0
France
State/province [95] 0 0
Besancon
Country [96] 0 0
France
State/province [96] 0 0
Bordeaux
Country [97] 0 0
France
State/province [97] 0 0
Caen Cedex
Country [98] 0 0
France
State/province [98] 0 0
Le Mans
Country [99] 0 0
France
State/province [99] 0 0
Montpellier
Country [100] 0 0
France
State/province [100] 0 0
Nice Cedex 2
Country [101] 0 0
France
State/province [101] 0 0
Paris
Country [102] 0 0
France
State/province [102] 0 0
Pierre Benite Cedex
Country [103] 0 0
France
State/province [103] 0 0
Rennes
Country [104] 0 0
France
State/province [104] 0 0
Saint Cloud
Country [105] 0 0
France
State/province [105] 0 0
Saint Herblain
Country [106] 0 0
France
State/province [106] 0 0
Toulouse Cedex 9
Country [107] 0 0
France
State/province [107] 0 0
Vandoeuvre les Nancy
Country [108] 0 0
Germany
State/province [108] 0 0
Berlin
Country [109] 0 0
Germany
State/province [109] 0 0
Bonn
Country [110] 0 0
Germany
State/province [110] 0 0
Dresden
Country [111] 0 0
Germany
State/province [111] 0 0
Erlangen
Country [112] 0 0
Germany
State/province [112] 0 0
Essen
Country [113] 0 0
Germany
State/province [113] 0 0
Frankfurt am Main
Country [114] 0 0
Germany
State/province [114] 0 0
Frankfurt
Country [115] 0 0
Germany
State/province [115] 0 0
Freiburg
Country [116] 0 0
Germany
State/province [116] 0 0
Hamburg
Country [117] 0 0
Germany
State/province [117] 0 0
Heidelberg
Country [118] 0 0
Germany
State/province [118] 0 0
Kiel
Country [119] 0 0
Germany
State/province [119] 0 0
Koblenz Am Rhein
Country [120] 0 0
Germany
State/province [120] 0 0
Leipzig
Country [121] 0 0
Germany
State/province [121] 0 0
Mainz Am Rhein
Country [122] 0 0
Germany
State/province [122] 0 0
Mannheim
Country [123] 0 0
Germany
State/province [123] 0 0
Muenster
Country [124] 0 0
Germany
State/province [124] 0 0
Neu-Isenburg
Country [125] 0 0
Germany
State/province [125] 0 0
Paderborn
Country [126] 0 0
Germany
State/province [126] 0 0
Rostock
Country [127] 0 0
Germany
State/province [127] 0 0
Troisdorf
Country [128] 0 0
Hungary
State/province [128] 0 0
Budapest
Country [129] 0 0
Hungary
State/province [129] 0 0
Gyor
Country [130] 0 0
Hungary
State/province [130] 0 0
Kecskemét
Country [131] 0 0
Hungary
State/province [131] 0 0
Miskolc
Country [132] 0 0
Hungary
State/province [132] 0 0
Nyíregyháza
Country [133] 0 0
Hungary
State/province [133] 0 0
Szolnok
Country [134] 0 0
India
State/province [134] 0 0
Ahmedabad
Country [135] 0 0
India
State/province [135] 0 0
Bangalore
Country [136] 0 0
India
State/province [136] 0 0
Belagavi
Country [137] 0 0
India
State/province [137] 0 0
Bengaluru
Country [138] 0 0
India
State/province [138] 0 0
Calicut
Country [139] 0 0
India
State/province [139] 0 0
Gurgaon
Country [140] 0 0
India
State/province [140] 0 0
Mysuru
Country [141] 0 0
India
State/province [141] 0 0
Nashik
Country [142] 0 0
India
State/province [142] 0 0
New Delhi
Country [143] 0 0
Israel
State/province [143] 0 0
Haifa
Country [144] 0 0
Israel
State/province [144] 0 0
Jerusalem
Country [145] 0 0
Israel
State/province [145] 0 0
Petah Tikva
Country [146] 0 0
Israel
State/province [146] 0 0
Ramat Gan
Country [147] 0 0
Israel
State/province [147] 0 0
Tel-Aviv
Country [148] 0 0
Italy
State/province [148] 0 0
Aviano
Country [149] 0 0
Italy
State/province [149] 0 0
Bergamo
Country [150] 0 0
Italy
State/province [150] 0 0
Candiolo
Country [151] 0 0
Italy
State/province [151] 0 0
Genova
Country [152] 0 0
Italy
State/province [152] 0 0
Livorno
Country [153] 0 0
Italy
State/province [153] 0 0
Milan
Country [154] 0 0
Italy
State/province [154] 0 0
Napoli
Country [155] 0 0
Italy
State/province [155] 0 0
Padova
Country [156] 0 0
Italy
State/province [156] 0 0
Rozzano
Country [157] 0 0
Italy
State/province [157] 0 0
Udine
Country [158] 0 0
Japan
State/province [158] 0 0
Akashi-shi
Country [159] 0 0
Japan
State/province [159] 0 0
Aomori-shi
Country [160] 0 0
Japan
State/province [160] 0 0
Bunkyo-ku
Country [161] 0 0
Japan
State/province [161] 0 0
Chiba-shi
Country [162] 0 0
Japan
State/province [162] 0 0
Chuo-ku
Country [163] 0 0
Japan
State/province [163] 0 0
Fukushima-shi
Country [164] 0 0
Japan
State/province [164] 0 0
Hidaka-shi
Country [165] 0 0
Japan
State/province [165] 0 0
Hiroshima-shi
Country [166] 0 0
Japan
State/province [166] 0 0
Isehara-shi
Country [167] 0 0
Japan
State/province [167] 0 0
Kagoshima-shi
Country [168] 0 0
Japan
State/province [168] 0 0
Kawasaki-shi
Country [169] 0 0
Japan
State/province [169] 0 0
Kobe-shi
Country [170] 0 0
Japan
State/province [170] 0 0
Koto-ku
Country [171] 0 0
Japan
State/province [171] 0 0
Kurume-shi
Country [172] 0 0
Japan
State/province [172] 0 0
Kyoto-shi
Country [173] 0 0
Japan
State/province [173] 0 0
Matsuyama-shi
Country [174] 0 0
Japan
State/province [174] 0 0
Nagoya-shi
Country [175] 0 0
Japan
State/province [175] 0 0
Niigata-shi
Country [176] 0 0
Japan
State/province [176] 0 0
Nishinomiya-shi
Country [177] 0 0
Japan
State/province [177] 0 0
Okayama
Country [178] 0 0
Japan
State/province [178] 0 0
Osaka-shi
Country [179] 0 0
Japan
State/province [179] 0 0
Ota-shi
Country [180] 0 0
Japan
State/province [180] 0 0
Sapporo-shi
Country [181] 0 0
Japan
State/province [181] 0 0
Sendai-shi
Country [182] 0 0
Japan
State/province [182] 0 0
Shinagawa-ku
Country [183] 0 0
Japan
State/province [183] 0 0
Shinjuku-ku
Country [184] 0 0
Japan
State/province [184] 0 0
Shizuoka
Country [185] 0 0
Japan
State/province [185] 0 0
Tsu-shi
Country [186] 0 0
Japan
State/province [186] 0 0
Yokohama-shi
Country [187] 0 0
Korea, Republic of
State/province [187] 0 0
Cheonan-si
Country [188] 0 0
Korea, Republic of
State/province [188] 0 0
Daegu
Country [189] 0 0
Korea, Republic of
State/province [189] 0 0
Goyang-si
Country [190] 0 0
Korea, Republic of
State/province [190] 0 0
Seoul
Country [191] 0 0
Mexico
State/province [191] 0 0
Acapulco
Country [192] 0 0
Mexico
State/province [192] 0 0
Alc. Cuauhtémoc
Country [193] 0 0
Mexico
State/province [193] 0 0
Del. Cuauhtemoc
Country [194] 0 0
Mexico
State/province [194] 0 0
Estado de México
Country [195] 0 0
Mexico
State/province [195] 0 0
Guadalajara Jalisco
Country [196] 0 0
Mexico
State/province [196] 0 0
Guadalajara
Country [197] 0 0
Mexico
State/province [197] 0 0
Metepec
Country [198] 0 0
Mexico
State/province [198] 0 0
Mexico
Country [199] 0 0
Mexico
State/province [199] 0 0
MEX
Country [200] 0 0
Mexico
State/province [200] 0 0
Nuevo Leon
Country [201] 0 0
Peru
State/province [201] 0 0
Arequipa
Country [202] 0 0
Peru
State/province [202] 0 0
Lima
Country [203] 0 0
Philippines
State/province [203] 0 0
Baguio City
Country [204] 0 0
Philippines
State/province [204] 0 0
Cebu City
Country [205] 0 0
Philippines
State/province [205] 0 0
Davao City
Country [206] 0 0
Philippines
State/province [206] 0 0
Iloilo City
Country [207] 0 0
Philippines
State/province [207] 0 0
Manila
Country [208] 0 0
Philippines
State/province [208] 0 0
Quezon City
Country [209] 0 0
Philippines
State/province [209] 0 0
San Juan
Country [210] 0 0
Romania
State/province [210] 0 0
Bucharest
Country [211] 0 0
Romania
State/province [211] 0 0
Bucuresti
Country [212] 0 0
Romania
State/province [212] 0 0
Cluj-Napoca
Country [213] 0 0
Romania
State/province [213] 0 0
Constanta
Country [214] 0 0
Romania
State/province [214] 0 0
Floresti
Country [215] 0 0
Romania
State/province [215] 0 0
Iasi
Country [216] 0 0
Romania
State/province [216] 0 0
Timisoara
Country [217] 0 0
Russian Federation
State/province [217] 0 0
Moscow
Country [218] 0 0
Russian Federation
State/province [218] 0 0
Omsk
Country [219] 0 0
Russian Federation
State/province [219] 0 0
Saint Petersburg
Country [220] 0 0
Russian Federation
State/province [220] 0 0
Saint-Petersburg
Country [221] 0 0
Russian Federation
State/province [221] 0 0
Yaroslavl
Country [222] 0 0
Saudi Arabia
State/province [222] 0 0
Dammam
Country [223] 0 0
Saudi Arabia
State/province [223] 0 0
Jeddah
Country [224] 0 0
Saudi Arabia
State/province [224] 0 0
Makkah
Country [225] 0 0
Saudi Arabia
State/province [225] 0 0
Riyadh
Country [226] 0 0
South Africa
State/province [226] 0 0
Cape Town
Country [227] 0 0
South Africa
State/province [227] 0 0
George
Country [228] 0 0
South Africa
State/province [228] 0 0
Johannesburg
Country [229] 0 0
South Africa
State/province [229] 0 0
Parktown
Country [230] 0 0
South Africa
State/province [230] 0 0
Port Elizabeth
Country [231] 0 0
South Africa
State/province [231] 0 0
Pretoria
Country [232] 0 0
South Africa
State/province [232] 0 0
Rondebosch
Country [233] 0 0
South Africa
State/province [233] 0 0
Soweto
Country [234] 0 0
Spain
State/province [234] 0 0
Alicante
Country [235] 0 0
Spain
State/province [235] 0 0
Barcelona
Country [236] 0 0
Spain
State/province [236] 0 0
Madrid
Country [237] 0 0
Spain
State/province [237] 0 0
Majadahonda
Country [238] 0 0
Spain
State/province [238] 0 0
San Sebastian
Country [239] 0 0
Spain
State/province [239] 0 0
Sevilla
Country [240] 0 0
Sweden
State/province [240] 0 0
Göteborg
Country [241] 0 0
Sweden
State/province [241] 0 0
Stockholm
Country [242] 0 0
Sweden
State/province [242] 0 0
Uppsala
Country [243] 0 0
Sweden
State/province [243] 0 0
Växjö
Country [244] 0 0
Sweden
State/province [244] 0 0
Örebro
Country [245] 0 0
Taiwan
State/province [245] 0 0
Taichung
Country [246] 0 0
Taiwan
State/province [246] 0 0
Tainan
Country [247] 0 0
Taiwan
State/province [247] 0 0
Taipei
Country [248] 0 0
Taiwan
State/province [248] 0 0
Taoyuan
Country [249] 0 0
Turkey
State/province [249] 0 0
Adana
Country [250] 0 0
Turkey
State/province [250] 0 0
Ankara
Country [251] 0 0
Turkey
State/province [251] 0 0
Karsiyaka
Country [252] 0 0
Turkey
State/province [252] 0 0
Malatya
Country [253] 0 0
Turkey
State/province [253] 0 0
Samsun
Country [254] 0 0
United Kingdom
State/province [254] 0 0
Buckhurst Hill
Country [255] 0 0
United Kingdom
State/province [255] 0 0
Edinburgh
Country [256] 0 0
United Kingdom
State/province [256] 0 0
Guildford
Country [257] 0 0
United Kingdom
State/province [257] 0 0
London
Country [258] 0 0
United Kingdom
State/province [258] 0 0
Maidstone
Country [259] 0 0
United Kingdom
State/province [259] 0 0
Manchester
Country [260] 0 0
United Kingdom
State/province [260] 0 0
Swansea
Country [261] 0 0
United Kingdom
State/province [261] 0 0
Taunton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.
Trial website
https://clinicaltrials.gov/study/NCT04784715
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04784715